| gap-pubmed-20260410- | What upstream signals activate DLK specifically in chronically demyelinated but | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the developmental trajectory linking early cognitive delays to later Alz | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does seasonal variation in sleep length depend on rs12506228 genotype in inf | open | 0.73 | 0.00 | 2026-04-10 | 0 | | circadian-biology |
| gap-pubmed-20260410- | How does the rs12506228 variant mechanistically link reduced MT1 receptors to im | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How does the epigenetic neural signature mechanistically link to poor prognosis | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | Why do high-neural glioblastomas exhibit increased functional connectivity and w | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What molecular mechanisms drive neuron-to-glioma synapse formation in high-neura | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neuro-oncology |
| gap-pubmed-20260410- | What distinguishes astrocyte-mediated from microglia-mediated inflammation in AD | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do astrocytes coordinate their dual roles in neurovascular coupling and syna | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurovascular-biology |
| gap-pubmed-20260410- | What molecular mechanisms determine whether astrocytes adopt harmful A1 vs prote | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does arimoclomol improve cell viability through NPC1-independent pathways in | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the precise cellular interactions and molecular targets of arimoclomol | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do competitive versus allosteric p5 inhibition mechanisms differ in therapeu | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines p5 peptide's selective inhibition of pathological CDK5-p25 versu | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the 13 identified genes converge on common pathways to produce the CP mot | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What mechanisms explain why CP masqueraders have higher genetic diagnostic yield | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | Why does hypotonic-ataxic CP subtype show differential prevalence across cryptog | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | Does the PGC-1α-Pitx3-BDNF pathway disruption occur in human PD and other neurod | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanism links PGC-1α overexpression to Pitx3 downregulation in | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does PGC-1α overexpression paradoxically increase MPTP toxicity despite enha | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does MLKL contribute to neuroinflammation through necroptosis-independent mechan | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does MLKL inhibition upregulate Nrf2 signaling independently of its necropto | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Does netrin-1's anti-inflammatory effect occur independently of or through Wnt/β | open | 0.77 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which netrin-1 receptors mediate the neuroprotective effects via Wnt signaling a | open | 0.82 | 0.00 | 2026-04-10 | 0 | | spinal-cord-injury |
| gap-pubmed-20260410- | How does netrin-1 mechanistically activate Wnt/β-catenin signaling in spinal cor | open | 0.80 | 0.00 | 2026-04-10 | 0 | | spinal-cord-injury |
| gap-pubmed-20260410- | What is the mechanistic link between mitochondrial dynamics and IRF/IFN-β pathwa | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does elevated ATP paradoxically promote cellular senescence instead of enhan | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the selective vulnerability of specific neuronal populations to | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does inflammasome hyperactivation mechanistically amplify misfolded protein | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific mechanisms distinguish neurodegeneration-associated inflammasome a | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What biological mechanisms underlie the gene expression patterns that predict di | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurogenetics |
| gap-pubmed-20260410- | Why do genes previously implicated in disease show false associations, and what | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurogenetics |
| gap-pubmed-20260410- | How do Gap43 upregulation and mTOR activation mechanistically link to cholinergi | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | Why do higher UV-328 concentrations paradoxically reduce neurotoxicity despite i | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-pubmed-20260410- | Which proteomic and metabolomic signatures in CSF/plasma predict CTE risk after | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | biomarker-discovery |
| gap-pubmed-20260410- | How can machine learning algorithms reliably distinguish CTE from Alzheimer's ta | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroimaging |
| gap-pubmed-20260410- | What molecular mechanisms distinguish CTE tau accumulation patterns from other t | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What strategies can overcome blood-brain barrier penetration limitations of cGAS | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can cGAS-STING inhibitors achieve therapeutic selectivity without disrupting | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What molecular mechanisms determine whether cGAS-STING activation is neuroprotec | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Can these plasma p-tau assays maintain performance across diverse populations an | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What biological mechanisms make p-tau217 superior to p-tau181 and p-tau231 as AD | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does mass spectrometry-based p-tau217 dramatically outperform immunoassays f | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do 97% of previously tested ALS drugs fail in both iPSC models and clinical | resolved | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What synergistic mechanisms make baricitinib, memantine, and riluzole effective | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the correlation between iPSC motor neuron deg | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do within-sample heterogeneity patterns differ between blood and brain tissu | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What biological mechanisms link DNA methylation heterogeneity patterns to aging | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Do other SAMs use conformational switching mechanisms similar to MDGA1? | open | 0.74 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do different 3D conformations of MDGA1 mechanistically control protein-prote | open | 0.79 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |